comparemela.com

Latest Breaking News On - துணை நிர்வகித்தல் ஆசிரியர் - Page 17 : comparemela.com

Boost Endocrine Therapy in Male Breast Cancer?

email article Combination endocrine therapy reduced estradiol to nearly undetectable levels in men with hormone receptor (HR)-positive breast cancer, though quality of life and sexual function appeared to suffer, a phase II study in Germany showed. In the randomized MALE trial of over 50 patients, median estradiol levels decreased by 85% with tamoxifen plus a gonadotropin-releasing hormone analogue (GnRHa) after 3 months of therapy, and by 72% with an aromatase inhibitor (AI) plus GnRHa, while increasing by 67% with tamoxifen alone ( P

KRAS Inhibitor Continues to Impress in NSCLC

More than a third of patients with pretreated non-small cell lung cancer (NSCLC) and a KRAS G12C mutation responded to the investigational agent sotorasib, findings from a phase II study showed. Among 126 NSCLC patients with locally advanced or metastatic disease, most of whom had their disease progress following treatment with both chemotherapy and a checkpoint inhibitor, 37.1% had a confirmed response to the KRAS G12C inhibitor (95% CI 28.6-46.2), including complete responses in 2.4%, reported Bob T. Li, MD, PhD, of Memorial Sloan Kettering Cancer Center in New York City. An additional 43.5% achieved stable disease as their best response, for a disease control rate of 81% (95% CI 72.6-87.2%), according to findings presented at the virtual World Conference on Lung Cancer (WCLC).

Customized Adjuvant Chemo Falls Short in Early Lung Cancer

email article A pharmacogenomic-driven approach for adjuvant chemotherapy in early-stage non-small cell lung cancer (NSCLC) significantly reduced treatment-related toxicity but failed to improve survival in the international, phase III ITACA trial. Among nearly 800 patients with stage II-IIIA disease who achieved a complete resection, median overall survival (OS) reached 96.4 months in the tailored chemotherapy arm versus 83.5 months with a standard cisplatin-based doublet (HR 0.76, 95% CI 0.55-1.04), reported Silvia Novello, MD, PhD, of the University of Torino at San Luigi Gonzaga Hospital in Italy. Recurrence-free survival (RFS) reached 64.4 months in the tailored arm, where patients received one of four different treatments based on their mRNA expression levels of excision repair cross complementation 1 (ERCC1) and thymidylate synthase (TS), as compared with 41.5 months in the control arm (HR 0.94, 95% CI 0.74-1.20).

Gains in Lung Cancer Survival Extend to Low-Income Patients

Eminent personalities to attend TV9 Network Conclave What Bengal Thinks Today

Home Minister Amit Shah on guest list too 29 Jan, 2021 - 04:21 PM IST     |     By indiantelevision.com Team     Union Home Minister Shri Amit Shah will attend the first ever conclave organised by TV9 Network in Bengal, India’s No.1 news network named, “What Bengal Thinks Today” on Saturday, 30th January 2021 at ITC Sonar. TV9 Bangla, the newly launched Bengali channel of TV9 Network has initiated this day long think fest where top politicians, thought leaders and opinion makers will discuss issues related to upcoming Assembly Election of West Bengal, “Banga Juddho Gadir Lorai” TV9 has initiated this intellectual meet based on the famous quote of the eminent congress leader Gopal Krishna Gokhale, What Bengal thinks today, India thinks tomorrow”. The prime focus of this conclave is upcoming election of West Bengal. Eminent leaders from all major political parties of West Bengal will attend this intellectual session. The event will emphasize on many issues

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.